Navigation Links
Conrad J. Heilman to Succeed Joseph S. Tempio as President and CEO of Tunnell Consulting

KING OF PRUSSIA, Pa., Nov. 13 /PRNewswire/ -- The Board of Directors of Tunnell Consulting, Inc. today announced that Conrad J. Heilman, Ph.D., will succeed Joseph S. Tempio, Ph.D. as President and Chief Executive Officer, effective July 2009. Heilman will serve immediately as Chief Operating Officer and retain that post until he becomes President and CEO.

Heilman currently serves as Senior Vice President of the Life Sciences Strategic Operating Unit (SOU) with responsibility for the entire SOU including the firm's offices in King of Prussia, California, and Puerto Rico. Since joining the firm in 2000 as a Managing Consultant, he has played an increasingly important role. He spearheaded multi-million dollar projects for respected international firms and partnered with key clients to develop and implement initiatives to improve operational performance and regulatory compliance. Heilman was instrumental in securing a contract with the National Institutes of Health (NIH) and a five-year $32 million dollar contract with the Department of Health and Human Services (HHS) to support the federal government's pandemic flu preparedness initiative.

"Conrad has had a tremendous impact on Tunnell and has done an excellent job of building our Life Sciences Strategic Operating Unit. His vision and willingness to take risks has extended our reach into the public sector with his initial involvement with HHS," said Tempio, who will continue as Chairman and will work closely with Heilman to ensure a smooth transition to President and CEO. "Conrad is a natural leader whose accomplishments in research, development, manufacturing, and regulatory issues make him ideally suited to managing Tunnell. The Board is confident that he will do a superb job in representing the firm to its clients and in providing them with exemplary service and innovative solutions to their most complex problems."

Prior to Tunnell, Heilman held senior positions in a number of companies. He was President of Quality Biotech Inc., Vice President of Research for Pro- Virus, a Director of Applied Biotechnology at DuPont Merck Pharmaceutical Co., and held other managerial and research positions for E.I. DuPont De Nemours, American Cyanamid, and Litton Bionetics.

Heilman's educational background in life sciences is extensive. A graduate of Long Island University with a B.S. degree in Biology, he earned his M.S. degree in Immunology from the University of Pennsylvania, and a Ph.D. in Pathobiology from Johns Hopkins University. He has published numerous articles in peer-reviewed journals and has a number of issued patents.

"Joe Tempio has guided the firm through one of its greatest growth periods and nurtured an environment that has driven profitability," Heilman said.

In 1999 Tempio joined Tunnell as head of a new practice - Life Sciences Technical Services. Under his direction, the unit experienced a steady and healthy growth, and in 2004 Tunnell adopted a new strategy to focus on consulting exclusively in life sciences. To spur more growth, Tempio restructured the organization into three strategic operating units. One of the units he established was a Government Services operating unit with offices in Bethesda. Md.- which serves the life sciences segments of the federal government. In 2006, Tempio expanded operations by opening offices in San Diego and San Juan, Puerto Rico to better serve the unique needs of the life sciences community. Between 2004 - the year Tempio was appointed President and CEO - and 2008, Tunnell expects revenues will have increased by almost 100 percent.

"It is with great honor, excitement, and enthusiasm that I take on this new role and responsibilities of leading Tunnell as it moves forward to a new phase of growth and development," said Heilman. "As we continue to grow and expand in other areas, we also realize that the life sciences industry is at a crossroads, with unprecedented changes. With increased competition among pharmaceutical companies, soaring health care costs, safety and patient issues, the climate is challenging but also offers exciting opportunities for the firm. With our depth of experience and focus in the life sciences, Tunnell is uniquely positioned to respond and adapt to the changing environment and help our clients solve their most complex problems."

About Tunnell Consulting

King of Prussia, PA-based Tunnell Consulting integrates strategic, technical, process and organizational skills to boost its clients' business performance. Founded in 1962, Tunnell focuses on the life sciences industry and government agencies, designing and implementing sustainable solutions that improve operating performance. The firm draws on the expertise of its accomplished multi-disciplinary professionals with experience in industry, government and research. Working with many of the world's leading companies and the public sector, Tunnell implements value-added, cost-effective solutions that fit the unique needs of each client they serve. More information may be found at

SOURCE Tunnell Consulting
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PCMA Statement on Baucus-Conrad Comparative Effectiveness Legislation
2. Conrad A. Conrad Elected Chairman of the Board for Rural/Metro Corporation
3. Front Line Caregiver Coalition Thanks Sens. Conrad, Coleman and Reps. Pomeroy, Capito and Berkley for Leading Bipartisan Hill Effort to Stop Bush Administrations Damaging Medicare Cuts
4. Stroller Strides(R) Franchises Succeed Despite Economic Climate
5. Interventions to Promote Breast-Feeding Succeed
6. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
7. Programs succeed in reducing risky sex among HIV-positive minority men
8. Three-Day Strike by Hundreds of Security Officers at Kaiser Hospitals Succeeds in Raising Red Flag About Unfair Labor Practices
9. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
10. Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives
11. Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... --  MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), a ... an Investigational New Drug Application (IND) with the U.S. ... fully human antibody product HuMab 5B1 as a therapeutic ... the Phase I clinical trial early in 2016. ... planned Phase I trial will evaluate the safety, tolerability ...
(Date:12/1/2015)... 2015  Booth #3506 – Claymount is featuring its full ... of the Radiological Society of North America ... Based in the Netherlands , Claymount is ... (NYSE: VAR ) and is one of the world,s ... state automatic exposure control systems for controlling dose during medical ...
(Date:12/1/2015)... , Dec. 1, 2015  Lexicon Pharmaceuticals, ... that top-line data from its TELECAST Phase ... in treating carcinoid syndrome in cancer patients ... clinical benefit observed in its pivotal TELESTAR ... a companion to TELESTAR primarily to provide ...
Breaking Medicine Technology: